CUPERTINO, Calif., May 28, 2020 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be
presenting at the Jefferies 2020 Virtual Health Care Conference,
Wednesday, June 3, 2020 at
10:00 a.m. EDT / 7:00 a.m. PDT. Institutional investors and
analysts that are participating in the conference may request a
virtual one-on-one meeting through the conference coordinators.
A live audio webcast of the presentation will be available by
accessing http://wsw.com/webcast/jeff126/drrx/
The live audio webcast of the presentation will also be
available by accessing DURECT's homepage at www.durect.com and
clicking on the "Investors" tab. If you are unable to
participate during the live webcast, the call will be archived on
DURECT's website in the "Event Calendar" of the "Investors"
section.
About DURECT Corporation
DURECT is a biopharmaceutical company committed to transforming
the treatment of acute organ injury and chronic liver diseases by
advancing novel and potentially lifesaving therapies based on its
endogenous epigenetic regulator program. DURECT's lead
candidate, DUR-928, has demonstrated the ability to regulate the
expression of genes involved in lipid metabolism, inflammatory
responses and cell survival. This drug candidate is currently in
Phase 2 development for the treatment of alcoholic hepatitis (AH),
and Phase 1 development for the treatment of nonalcoholic
steatohepatitis (NASH). We are also working with the FDA on
the design of a proof-of-concept Phase 2 trial of DUR-928 in
COVID-19 patients with acute liver or kidney injury. DURECT's
proprietary drug delivery technologies are designed to enable new
indications and enhanced attributes for small-molecule and biologic
drugs. A key product candidate in this category is
POSIMIR® (bupivacaine extended-release solution), an
investigational locally-acting, non-opioid analgesic intended to
provide up to three days of continuous pain relief after surgery.
DURECT has also entered into an agreement with Gilead
Sciences to develop and commercialize a long-acting injectable HIV
investigational product using DURECT's
SABER® technology. For more information about
DURECT, please visit www.durect.com.
DURECT Forward-Looking Statement
The statements in
this press release regarding the potential for DUR-928 to treat AH,
NASH or COVID-19 patients and plans for clinical development of
DUR-928, including plans to conduct a Phase 2 clinical trial of
DUR-928 in COVID-19 patients, and the potential benefits and uses
of our drug candidates, including the potential use of DUR-928 to
treat acute organ injuries such as AH, NASH and COVID-19 patients
with acute liver or kidney injury, are forward-looking statements
involving risks and uncertainties that can cause actual results to
differ materially from those in such forward-looking statements.
Potential risks and uncertainties include, but are not limited to,
the risks that future clinical trials of DUR-928 do not confirm the
results of trials conducted on small numbers of patients, are not
started when anticipated, take longer to conduct than anticipated,
do not generate similar positive results as generated in earlier
clinical or pre-clinical trials, or do not demonstrate the safety
or efficacy of DUR-928 in a statistically significant manner, the
risk of disruptions to our business operations resulting from the
COVID-19 pandemic, the risk that additional time and resources may
be required for development, testing and regulatory approval of
DUR-928, potential adverse effects arising from the testing or use
of our drug candidates, our potential failure to maintain our
collaborative agreements with third parties such as Gilead or
consummate new collaborations and risks related to our ability to
obtain capital to fund operations and expenses. Further information
regarding these and other risks is included in DURECT's Form 10-Q
filed on May 11, 2020 under the
heading "Risk Factors."
NOTE: POSIMIR® and SABER® are trademarks
of DURECT Corporation. Other referenced trademarks belong to
their respective owners. DUR-928 and POSIMIR are
investigational drug candidates under development and have not been
approved for commercialization by the U.S. Food and Drug
Administration or other health authorities for any indication.
View original
content:http://www.prnewswire.com/news-releases/durect-to-present-at-the-jefferies-2020-virtual-health-care-conference-301066563.html
SOURCE DURECT Corporation